These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34804158)

  • 1. DNA Methylation Modification Regulator-Mediated Molecular Clusters and Tumor Metabolic Characterization in Prostate Cancer.
    Zhang Y; Liang X; Zhang L; Wang D
    J Oncol; 2021; 2021():2408637. PubMed ID: 34804158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer.
    Meng Q; Lu YX; Ruan DY; Yu K; Chen YX; Xiao M; Wang Y; Liu ZX; Xu RH; Ju HQ; Qiu MZ
    Mol Ther Nucleic Acids; 2021 Jun; 24():695-710. PubMed ID: 33996253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation regulator-mediated modification pattern defines tumor microenvironment immune infiltration landscape in colon cancer.
    Yuan S; Gao Y; Xia Y; Wang Z; Wang X
    Front Genet; 2022; 13():1008644. PubMed ID: 36276973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.
    Shi R; Zhao H; Zhao S; Yuan H
    Aging (Albany NY); 2022 Jun; 14(12):5271-5291. PubMed ID: 35771147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer.
    Zhang Y; Liang X; Zhang L; Wang D
    Sci Rep; 2021 Nov; 11(1):22486. PubMed ID: 34795309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA5mC Regulator-Mediated Molecular Clusters and Tumor Microenvironment Signatures in Glioblastoma.
    Yu X; Che Y; Li W; Zhang P; Yu Y; Chen J; Gong T; Cao F
    Front Cell Dev Biol; 2022; 10():1055567. PubMed ID: 36425533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma.
    Yuan D; Wei Z; Wang Y; Cheng F; Zeng Y; Yang L; Zhang S; Li J; Tang R
    Front Oncol; 2021; 11():734873. PubMed ID: 34552879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma.
    Luo H; Ye M; Hu Y; Wu M; Cheng M; Zhu X; Huang K
    Aging (Albany NY); 2022 Sep; 14(19):7824-7850. PubMed ID: 36152044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model.
    Zhang Y; Zhang R; Liang F; Zhang L; Liang X
    Front Oncol; 2020; 10():598801. PubMed ID: 33324566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. m
    Li Z; Wei J; Zheng H; Gan X; Song M; Zhang Y; Kong L; Zhang C; Yang J; Jin Y
    Aging (Albany NY); 2022 Jan; 14(1):330-353. PubMed ID: 34979500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of DNA Methylation Molecular Features for Diagnosis and Prognosis in Gastric Cancer.
    Liu D; Li L; Wang L; Wang C; Hu X; Jiang Q; Wang X; Xue G; Liu Y; Xue D
    Front Genet; 2021; 12():758926. PubMed ID: 34745226
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of m
    Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
    Front Immunol; 2021; 12():782551. PubMed ID: 34975871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
    Quan Y; Zhang X; Ping H
    Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer.
    Zhang Q; Luan J; Song L; Wei X; Xia J; Song N
    J Cancer; 2021; 12(12):3575-3586. PubMed ID: 33995635
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma.
    Xu Q; Hu Y; Chen S; Zhu Y; Li S; Shen F; Guo Y; Sun T; Chen X; Jiang J; Huang W
    Front Mol Biosci; 2021; 8():683240. PubMed ID: 34124163
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
    Yin T; Zhao L; Yao S
    BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. m
    Ye X; Wang R; Yu X; Wang Z; Hu H; Zhang H
    Front Pharmacol; 2022; 13():1030766. PubMed ID: 36313300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer.
    Dong M; Shen W; Yang G; Yang Z; Li X
    Front Cell Dev Biol; 2022; 10():785058. PubMed ID: 35178386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.